Abstract: Synthetic enzymatic cascades are provided that continuously produce adenosine triphosphate (ATP) from a variety of fuel sources. The cascades are prepared by expressing one or more NADH-dependent dehydrogenases, polyphosphate NAD+ kinases (PPNK), NADPH oxidases, and particular reversible ATP-NAD+ kinases (NADK). The NADH-dependent dehydrogenases oxidize fuel sources such as formate and methanol while converting NAD+ to NADH. The PPNKs convert the NADH to NADPH. The NADPH oxidases convert NADPH to NADP+. The NADKs then convert the NADP+ to NAD+ while also facilitating conversion of adenosine diphosphate (ADP) or adenosine monophosphate (AMP) to ATP. Human NADK exhibits high affinity for NAD+ and is thus impeded in the generation of ATP products via product inhibition. Thus, pigeon, duck, and cat NADK isoforms are implemented in the cascade instead. The cascades generate a low-cost, continuous source ATP product for use in numerous in vitro applications such as cell-free protein production.

Abstract: This invention provides a process for sequencing single-stranded DNA by employing a nanopore and modified nucleotides.

Abstract: In various embodiments, the present invention relates generally to using bispecific antibodies in the prevention and treatment of HIV.

Abstract: An exemplary system, method, and computer-accessible medium for generating diagnostic data associated with a likelihood a patient(s) developing a mental disease(s) can be provided, which can include, for example, providing a visual patterns to the patient(s), receiving electroencephalogram (EEG) information from the patient(s) that can be based on the visual pattern(s); and generating the diagnostic data based on the EEG information.

Abstract: An exemplary system, method, and computer-accessible medium for detection of structural disorder(s) of patient(s) can be provided which can include, for example, receiving magnetic resonance imaging (MRI) information of the portion(s), generating gadolinium (“Gd”) enhanced map(s) based on the MRI information using a machine learning procedure(s), and detecting the structural disorder(s) of the patient(s) based on a GD contrast of the Gd enhanced map(s). The Gd enhanced map(s) can be a full dosage Gd enhanced map. The machine learning procedure can be a convolutional neural network. The MRI information can include (i) a low-dosage Gd MRI scan(s), or (ii) a Gd-free MRI scan(s). The Gd contrast can be generated in the Gd enhanced map(s) using a T2-weighted MRI image of the portion(s). Structural disorder(s) can include Stroke, tumor, trauma, infection, Multiple sclerosis and/or other inflammatory disease.

Abstract: Disclosed herein, inter alia, are nucleotide analogues, and methods of use thereof, having cleavable orthogonal linkers.

Abstract: The present subject matter relates to techniques for passive acoustic mapping. The disclosed system can include a focused ultrasound (FUS) transducer, a diagnostic phase array transducer, and a processor. The diagnostic phase array transducer can be configured to receive a cavitation signal induced from cavitation. The processor can be configured to generate a cavitation map based on a spatio-temporal cavitation intensity. The spatio-temporal cavitation intensity can be calculated using a spatial-temporal parallel programming. The spatial-temporal parallel programming can be performed by creating a thread for each pixel of the spatial-temporal map, calculating the spatio-temporal cavitation intensity at a location and a time point in each thread, and creating a cavitation map by integrating the spatial-temporal cavitation intensity over temporal pixels.

Abstract: The present disclosure provides, inter alia, a recombinant engineered deubiquitinase (DUB) and methods for treating or ameliorating an inherited ion channelopathy, such as long QT syndrome, Brugada syndrome, or cystic fibrosis, in a subject. Further provided are methods for screening mutations causing such inherited ion channelopathies for a trafficking-deficient mutation that is treatable by the recombinant engineered DUB disclosed herein.

Abstract: Certain exemplary embodiments of the present disclosure can provide an apparatus and method for generating at least one radiation can be provided. The exemplary apparatus and/or method can selectively kill and/or affect at least one virus. For example, a radiation source first arrangement can be provided which is configured to generate at least one radiation having one or more wavelengths provided in a range of about 200 nanometers (nm) to about 230 nm, and at least one second arrangement can be provided which is configured to prevent the at least one radiation from having any wavelength that is outside of the range can be provided or which can be substantially harmful to cells of the body.

Abstract: The present disclosure provides, inter alia, a recombinant engineered deubiquitinase (DUB) and methods for treating or ameliorating an inherited ion channelopathy, such as long QT syndrome, Brugada syndrome, or cystic fibrosis, in a subject. Further provided are methods for screening mutations causing such inherited ion channelopathies for a trafficking-deficient mutation that is treatable by the recombinant engineered DUB disclosed herein.

Abstract: Programmable bacterial cells that comprise a gene that regulates capsular polysaccharide nanoencapsulation of the bacterium linked to an exogenous promoter, wherein expression of the gene and the nanoencapsulation can be programmed or controlled by an external modulator of the exogenous promoter and related compositions and methods.

Abstract: Methods of targeting CD58 signaling to enhance antitumor immunity and overcome resistance to checkpoint blockade therapy. Gene signatures associated with immune fitness were identified. Markers and therapeutic targets for such immunotherapy resistance.

Abstract: Systems and methods for cavitation-guided opening of a targeted region of tissue within a primate skull are provided. In one example, a method includes delivering one or more microbubbles to proximate the targeted region, applying an ultrasound beam, using a transducer, through the skull of the primate to the targeted region to open the tissue, transcranially acquiring acoustic emissions produced from an interaction between the one or more microbubbles and the tissue, and determining a cavitation spectrum from the acquired acoustic emissions.

Abstract: An exemplary system, method and computer-accessible medium for harmonizing neuromelanin (NM) data using combat directly on a NM database or using combat generated coefficients to harmonize future data can include, for example, receiving imaging information of a brain of the patient(s), from one MRI scanner, receiving imaging information of a brain of the patient(s), from a second MRI scanner and using combat to harmonize the data between scanners against a reference dataset. The Neuromelanin (NM) concentration of the patient(s) can then be determined based on the harmonized data. The NM concentration can be determined using a voxel-wise analysis procedure. The voxel-wise analysis procedure can be used to determine a topographical pattern(s) within a substantia nigra (SN) of the brain of the patient(s).

Abstract: Methods, systems, and media for testing insider threat detection systems are provided.

Abstract: The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, the treatment of ischemic injury, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, diabetic cardiomyopathy, infections of the skin, peripheral vascular disease, stroke, asthma, and the like.

Abstract: Mechanisms for proving the correctness of software on relaxed memory hardware are provided, the mechanisms comprising: receiving a specification, a hardware model, and an implementation for the software to be executed on the relaxed memory hardware; evaluating the software using a sequentially consistent hardware model; evaluating the software using a relaxed memory hardware model and at least one of the following conditions: a data-race-free (DRF)-kernel condition; a no-barrier-misuse condition; a memory-isolation condition; a transactional-page-table condition; a write-once-kernel-mapping condition; and a weak-memory-isolation condition; and outputting an indication of whether the software is correct based on the evaluating the software using the sequentially consistent hardware model and the evaluating the software using the relaxed memory hardware model.

Abstract: The disclosed subject matter provides for genetically modified cells, e.g., fungal cells, that autonomously generates and/or secretes one or more skin therapeutics, and methods of use thereof. In certain embodiments, the present disclosure provides genetically-engineered fungal cells that generate and secrete growth factors, protease inhibitors, cytokines and/or chemokines and methods of use thereof, e.g., for treating skin conditions.

Abstract: The present invention provides a compound having the structure: wherein R1, R2, R3, R4, and R5 are each independently H, halogen, CF3 or C1-C4 alkyl; R6 is H, OH, or halogen; B is a substituted or unsubstituted heterobicycle, pyridazine, pyrazole, pyrazine, thiadiazole, or triazole, wherein the heterobicycle is other than chloro substituted indole; and the pyrazole, when substituted, is substituted with other than trifluoromethyl, or a pharmaceutically acceptable salt thereof.

Abstract: Provided herein are methods and compositions for treating and preventing vascular malformations including lymphatic, venous, capillary, arteriovenous, and combinations thereof. Methods of treatment and prevention include the administration of proteasome inhibitors, omipalisib, disulfiram, and agents which target genes in the PI3K/AKT/mTOR or RAS/RAF/MAPK pathways, including but not limited to Pik3ca, Pik3r3, Tsc2, Rasa1, Map2k2, and Glmn.